Anti-viral Drug Favipiravir Approved for COVID-19 Treatment

Antiviral medication favipiravir has been approved for treatment of mild to moderate COVID-19 patients in India, revealed sources.

In India, Glenmark Pharmaceuticals has approved Favipiravir for the treatment of mild to moderate COVID-19, revealed sources.

In a filing with the exchanges on Friday, Glenmark Pharmaceuticals said that it has just received the //manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug Favipiravir (FabiFlu) for the treatment of mild to moderate COVID-19 patients in the country.

Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.

‘Glenmark was the first pharmaceutical company in India to be given approval by the drug regulator to conduct Phase 3 clinical trial of Favipiravir antiviral tablets for COVID-19 patients. Patients from over 10 leading government and private hospitals were enrolled for the study. ’

This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of the accelerated approval process, considering the emergency situation and unmet medical needs of the COVID-19 outbreak, Glenmark said.

"It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation," the company said.

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation.

COVID-19: 340 Million People, 15% of 9MM Population, Face Risk of Severe Coronavirus
The US and the UK show the largest proportion of their population with underlying health conditions linked to severe outcomes of COVID-19 across the 9MM. These countries also rank in the top three countries most affected by death due to COVID-19 worldwide.

Glenmark has successfully developed the API and the formulations for the product through its inhouse R&D team.

Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. The molecule if commercialized, will be marketed under the brand name FabiFlu in India.

PM Discuss COVID-19 Situation
Prime Minister Narendra Modi discusses the coronavirus situation across the country at a high-level meeting here and discussed the future road map.

Source-IANS

Link Between Diabetic Ketoacidosis and COVID-19
Diabetic ketoacidosis is a common and potentially fatal complication in hospitalized patients with COVID-19, stated new study.